Novartis scoops up Opexa's stem cell program in $50M deal

Shares of Opexa Therapeutics got a badly needed bump after the biotech announced that it had struck a deal to sell its preclinical stem cell technology to Novartis for $4 million in upfront and technology transfer fees and around $50 million in potential milestone payments. Opexa will sign over a licensing pact it inked with the University of Chicago.

Opexa's lead therapy is Tovaxin, a T-cell vaccine for multiple sclerosis. Its stock jumped from 47 cents a share to 80 cents on the news.

"This represents a great opportunity for Opexa," said Neil K. Warma, CEO of The Woodlands, TX-based biotech. "Novartis is one of the premier pharmaceutical companies and the expertise they bring to this program will undoubtedly advance the technology significantly. This agreement will also allow us to firmly focus our attention on our key clinical asset, Tovaxin."

- check out the press release
- read the story from Reuters 

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.